家族性地中海热(FMF)的旧范式与新概念:2023年更新
本文综述家族性地中海热(FMF)的临床特征、诊断、遗传方式、发病机制与治疗进展,指出「FMF」命名、仅凭临床诊断、MEFV突变导致功能丧失及所有患者需终身治疗等旧范式已被新证据修正。
要点
- 「FMF」命名不再适用,该病已见于地中海盆地以外地区。
- 仅基于临床依据诊断FMF的观念已被证明错误。
- FMF中MEFV突变导致Pyrin蛋白功能丧失的旧范式实为功能获得性突变。
核心结论
- 识别MEFV基因及阐明其发病机制突破了旧范式,并以更精确的新见解取代之。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 「FMF」命名不再适用,因该病发现于地中海盆地以外。
- 仅基于临床依据诊断FMF的观念被证明错误。
- FMF中MEFV突变导致所编码Pyrin肽功能丧失的范式实为功能获得性突变。
- 作为遗传病FMF应终身治疗的概念对异合子患者亚群被证明不准确。
关键数值与推荐
- 秋水仙碱自1972年以来一直是该病的首选治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent attacks of fever and polyserositis. Its first description as a new entity was published by Siegal in 1945. Colchicine has been the treatment of choice for this disease since 1972. Significant progress has been made over the years in understanding FMF's clinical features, diagnosis, mode of inheritance, pathogenesis and therapeutic approach. However, many old paradigms related to FMF have proven inaccurate, leading to the emergence of new concepts that provide more precise insights. The term 'FMF' is no longer appropriate as the disease is found beyond the Mediterranean basin. The concept of diagnosis based only upon clinical ground proved to be wrong. The paradigm that MEFV mutations in FMF lead to loss of function of the encoded peptide pyrin turned out to be a gain of function mutation. Finally, the concept that as a genetic disease FMF should be treated for life was found to be inaccurate for the subpopulation of the heterozygote patients. Thus, the breakthroughs of identifying the gene associated with the disease (MEFV) and the deciphering of its pathogenesis revolutionized our old paradigms and replaced them with new and more precise insights.
引用
- Ben-Chetrit E. Old paradigms and new concepts in familial Mediterranean fever (FMF): an update 2023. Rheumatology (Oxford). 2024. PMID: 37725337. doi:10.1093/rheumatology/kead439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。